Empagliflozin for Chronic Kidney Disease (NDKD Trial)

"Eligible participants for this research effort must fall within the age range of 19 to 90 years. Notably, there are a total of 48 investigations tailored towards individuals below 18 years old and 496 studies focused on patients aged over 65."

"The safety rating assigned to Empagliflozin by our team at Power is 3, reflecting the advanced phase of this trial (Phase 4), which signifies approval for this treatment."

"For this trial, the investigators seek to enroll 60 individuals with chronic kidney disease aged between 19 and 90 years. Essential requirements include: age ranging from 20 to 90 years old, BMI falling within the range of 25-45, being of African American descent, having an estimated glomerular filtration rate (eGFR) between ≥30-90 mL/min/1.73 m2 as calculated by CKD-EPI equation, albuminuria levels equal to or exceeding 30 mg/g during screening, maintaining blood pressure under control at ≤140/90 mmHg while on a consistent antihypert"

"Indeed, the information available on clinicaltrials.gov highlights that this specific trial is in an active recruitment phase. Originally shared on February 2nd, 2024, and last modified on April 10th of the same year, the trial aims to enroll a total of 60 participants from a single site."

"Affirmative. Information found on clinicaltrials.gov indicates that this study is presently in search of participants. Originally listed on February 2nd, 2024, the trial's most recent update was on April 10th, 2024. A total of 60 individuals are sought for enrollment at a singular site."